ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers

Ashish M. Kamat, Paul K. Hegarty, Jason R. Gee, Peter E. Clark, Robert S. Svatek, Nicholas Hegarty, Shahrokh F. Shariat, Evanguelos Xylinas, Bernd J. Schmitz-Dräger, Yair Lotan, Lawrence C. Jenkins, Michael Droller, Bas W. Van Rhijn, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Context and objective: To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions: Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.

Original languageEnglish (US)
Pages (from-to)4-15
Number of pages12
JournalEuropean Urology
Volume63
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Referral and Consultation
Cystoscopy
Narrow Band Imaging
Molecular Medicine
Recurrence
Urinary Tract
Cell Biology
Neoplasms
Therapeutics
Fluorescence
Research Personnel
Urine
Pathology
Technology
Physicians
Light
Costs and Cost Analysis
Growth

Keywords

  • Bladder cancer
  • Detection
  • Diagnosis
  • Markers
  • Recommendations
  • Screening

ASJC Scopus subject areas

  • Urology

Cite this

Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., ... Karakiewicz, P. I. (2013). ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. European Urology, 63(1), 4-15. https://doi.org/10.1016/j.eururo.2012.09.057

ICUD-EAU international consultation on bladder cancer 2012 : Screening, diagnosis, and molecular markers. / Kamat, Ashish M.; Hegarty, Paul K.; Gee, Jason R.; Clark, Peter E.; Svatek, Robert S.; Hegarty, Nicholas; Shariat, Shahrokh F.; Xylinas, Evanguelos; Schmitz-Dräger, Bernd J.; Lotan, Yair; Jenkins, Lawrence C.; Droller, Michael; Van Rhijn, Bas W.; Karakiewicz, Pierre I.

In: European Urology, Vol. 63, No. 1, 01.2013, p. 4-15.

Research output: Contribution to journalArticle

Kamat, AM, Hegarty, PK, Gee, JR, Clark, PE, Svatek, RS, Hegarty, N, Shariat, SF, Xylinas, E, Schmitz-Dräger, BJ, Lotan, Y, Jenkins, LC, Droller, M, Van Rhijn, BW & Karakiewicz, PI 2013, 'ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers', European Urology, vol. 63, no. 1, pp. 4-15. https://doi.org/10.1016/j.eururo.2012.09.057
Kamat, Ashish M. ; Hegarty, Paul K. ; Gee, Jason R. ; Clark, Peter E. ; Svatek, Robert S. ; Hegarty, Nicholas ; Shariat, Shahrokh F. ; Xylinas, Evanguelos ; Schmitz-Dräger, Bernd J. ; Lotan, Yair ; Jenkins, Lawrence C. ; Droller, Michael ; Van Rhijn, Bas W. ; Karakiewicz, Pierre I. / ICUD-EAU international consultation on bladder cancer 2012 : Screening, diagnosis, and molecular markers. In: European Urology. 2013 ; Vol. 63, No. 1. pp. 4-15.
@article{003764175a87404d9453c6045377f883,
title = "ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers",
abstract = "Context and objective: To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions: Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.",
keywords = "Bladder cancer, Detection, Diagnosis, Markers, Recommendations, Screening",
author = "Kamat, {Ashish M.} and Hegarty, {Paul K.} and Gee, {Jason R.} and Clark, {Peter E.} and Svatek, {Robert S.} and Nicholas Hegarty and Shariat, {Shahrokh F.} and Evanguelos Xylinas and Schmitz-Dr{\"a}ger, {Bernd J.} and Yair Lotan and Jenkins, {Lawrence C.} and Michael Droller and {Van Rhijn}, {Bas W.} and Karakiewicz, {Pierre I.}",
year = "2013",
month = "1",
doi = "10.1016/j.eururo.2012.09.057",
language = "English (US)",
volume = "63",
pages = "4--15",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - ICUD-EAU international consultation on bladder cancer 2012

T2 - Screening, diagnosis, and molecular markers

AU - Kamat, Ashish M.

AU - Hegarty, Paul K.

AU - Gee, Jason R.

AU - Clark, Peter E.

AU - Svatek, Robert S.

AU - Hegarty, Nicholas

AU - Shariat, Shahrokh F.

AU - Xylinas, Evanguelos

AU - Schmitz-Dräger, Bernd J.

AU - Lotan, Yair

AU - Jenkins, Lawrence C.

AU - Droller, Michael

AU - Van Rhijn, Bas W.

AU - Karakiewicz, Pierre I.

PY - 2013/1

Y1 - 2013/1

N2 - Context and objective: To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions: Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.

AB - Context and objective: To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions: Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.

KW - Bladder cancer

KW - Detection

KW - Diagnosis

KW - Markers

KW - Recommendations

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84870543907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870543907&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.09.057

DO - 10.1016/j.eururo.2012.09.057

M3 - Article

C2 - 23083902

AN - SCOPUS:84870543907

VL - 63

SP - 4

EP - 15

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -